Pfizer, Arvinas join SERD club with Veppanu approval

IlluminaFinal Trades: Uber, Exxon, Illumina and Diamondback Energy - CNBC

Endpoints NewsFDA search for new CBER head focused on small group of final candidates

FierceBiotech‘A concerted industry-government effort’: Strand Therapeutics CEO Jake Becraft on FDA’s IND reform and China

BioPharma DiveCelcuity strengthens case for ASCO-spotlighted breast cancer drug

Endpoints NewsSupreme Court restores mifepristone access by mail

Clinical OMICsBiomarker of Epigenetic Aging Could Signal Depression

AmgenPfizer vs. Amgen: Which Big Pharma Stock Is the Better Value Right Now? - TIKR.com

FierceBiotechMirum maps FDA path after anti-itch candidate scores ph. 2 win

Samsung BiologicsCDMO Samsung Biologics estimates $102M impact stemming from ongoing union strike - Fierce Pharma

NovartisAfter March cuts, Novartis trims another 60 roles at US headquarters - Fierce Pharma

FierceBiotechTakeda pivotal trial win improves convenience for PID patients relative to HyQvia

BioWorldUCB onboards more autoimmune TCEs with $2.2B Candid buy